Highlights of Cardiology Research At Genesis · Grant from Genesis Research Program) Characteristics Gender - Male 109 36 13.9 CAD - Yes 109 69 63.3 Prior PCI - Yes 109 26 23.9 Prior
Post on 07-Jul-2020
1 Views
Preview:
Transcript
Highlights of Cardiology Research At Genesis
Nicolas W Shammas, MD, MS, FACC
Research Director, MCRF
Interventional Cardiologist, Cardiovascular Medicine, PC
Genesis Heart Institute
Bioabsorbable Stents
3
Absorb BVS
Bioresorbable Stents
BVS
REVA
Biotronik
BIT
Igaki-Tamai PLA
Tyrosine-
Policarbonate
PAE-Salicylate
Magnesium
PLA
BL 2Y
Resolved ISA
Non Discernible
Persistent
ISA ISA incomplete
stent apposition
Bioresorption and vessel wall integration are a reality.
Why Degradable Stents?
Decrease late adverse events
– Late thrombosis
– Hypersensitivity reactions (chronic inflammation)
– Stent fractures
Does not restrict arterial remodeling
Permits non-invasive imaging of artery
Permits bypass surgery in future
Why Degradable Stents?
Study design
7
ABSORB IIIRandomized 2:1 (BVS : XIENCE)
N~2250
Primary EP:
1 yr TLF Non-inferiority of BVS vs. XIENCE
TLF=Cardiac death, Non fatal MI attributable to target vessel or TLR
General Inclusion
Subject must have evidence of myocardial ischemia (e.g.,
stable or unstable angina, post-infarct angina or silent
ischemia, as identified by chest pain or functional studies
such as a stress test), suitable for elective PCI.
Subjects with stable angina or silent ischemia and < 70%
diameter stenosis must have objectives sign of ischemia
as determined by one of the following, echocardiogram,
nuclear scan, ambulatory ECG or stress ECG). In the
absence of noninvasive ischemia, fractional flow reserve
(FFR) must be done and indicative of ischemia.
8
30d 6 mo 12 mo 24 mo 36 mo 48 mo 60 mo
Clinical follow-up (*ECG)
PRO follow-up
(PRO = patient reported outcomes)
A-III Cohort ObjectivePivotal trial to support the US pre-market approval of Absorb BVS Randomized 2:1 ABSORB:XIENCE
Primary EndpointTarget lesion failure at 1-year (composite of cardiac death, target vessel MI or ischemia driven-TLR)
TreatmentUp to two de novo lesions in different epicardial vessels. No planned overlap allowed
Subjects and Location 2000 primary analysis subjects; US and Outside the US sites
ABSORB III – Randomized Subjects
9
No ECG
*
(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients
Study Design:
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver,
Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Arms Assigned Intervention
Experimental: Betrixaban Drug: Betrixaban Betrixaban 80 mg PO QD for 35 day + 7 days.
Enoxaparin Placebo: Once daily, 6-14 days
Active Comparator: Enoxaparin Drug: Enoxaparin Enoxaparin 40 mg SC QD for 10 4 days.
Betrixaban Placebo: once daily, 35 days
Primary Outcome Measures:
Composite of VTE (DVT and/or PE) and VTE
Death [ Time Frame: Occurrence of any of
the events through the Day 35 visit ]
Secondary Outcome Measures:
Number of patients with symptomatic VTE
[ Time Frame: The occurrence through the
Day 35 visit ]
• Inclusion Criteria:men and non-pregnant, non-breastfeeding women
anticipated to be severely immobilized for at least 24 hours after randomization
hospitalized with one of the following
– congestive heart failure
– acute respiratory failure,
– acute infection without septic shock,
– acute rheumatic disorders
– acute ischemic stroke with lower extremity hemiparesis or hemi paralysis
• Exclusion Criteria:a condition requiring prolonged anticoagulation or anti-platelets
active bleeding or at high risk of bleeding
contraindication to anticoagulant therapy
general conditions in which subjects are not suitable to participate in the study
PCI over 90 Protocol (IIS supported by a Grant from Genesis Research Program)
Characteristics
Gender - Male 109 36 13.9
CAD - Yes 109 69 63.3
Prior PCI - Yes 109 26 23.9
Prior CABG - Yes 107 20 18.7
Previous MI - Yes 109 28 25.7
Prior Family Hx - Yes 109 7 6.4
Renal Insufficiency - Yes 109 36 33
Renal Failure -Yes 109 7 6.4
PVD - Yes 109 12 11
HTN - Yes 109 88 80.7
CVD - Yes 109 25 22.9
Hyperlipidemia - Yes 109 49 45
COPD 109 16 14.7
Cardiomyopathy - Yes 109 8 7.3
Heart Failure - Yes 109 33 30.3
Atrial fibrillation - Yes 109 24 22
Tobacco Use - Past 109 23 21.1
DM - Yes 109 26 23.9
Dementia - Yes 109 17 15.6
Valvular Disease - Yes 109 20 18.3
Pacemaker - Yes 109 12 11
Indications for
Angiography n Percent
None 54 50
Unstable Angina/NSTEMI 45 41.7
STEMI 7 6.5
Abnormal perfusion 2 1.9
Procedural/Angiographic Selected Data
N Mean SD
EF (Cath and Echo) 77 46.4 13.8
Total Lesion Length per patient 50 63.9 42
Number of Denovo Lesions per patient 50 2.5 2.1
Door to balloon time for STEMI 5 57.2 28.2
Pre-lesion severity 149 85.5 13.2
Syntax 41 23.2 14.5
n Percent
PCI Complications
None 43 72.9
pRBC's transfusion/anemia 4 6.8
renal failure/ renal insufficency 5 8.5
major bleeding 1 1.7
pseudoaneurysm 2 3.4
cardiac tamponade 1 1.7
arrythmia 1 1.7
pericardial effusion 1 1.7
dissection and thrombus of CFA 1 1.7
Ongoing Analysis
Died vs Lived: predictors of
Mortality and MAE in-
hospital and on follow-up
Cath vs Conservative Rx
Disposition after discharge
Centurians?
Publications since last Research Conference
Shammas NW, Hauber W. How to Implement an Office-Based Vein Program. J Invasive Cardiol 2014 (In Print)
Banerjee S, Sarode K, Das T, Hadidi O, Thomas R, Vinas A, Garg P, Mohammad A, Baig MS, Shammas NW,Brilakis ES. Crossing of Infrainguinal Peripheral Arterial Chronic Total Occlusion with VianceT Blunt Microdissection Catheter. J Invasive Cardiol;2014 (In print)
Banerjee S, Sarode K, Das T, Hadidi O, Thomas R, Vinas A, Garg P, Mohammad A, Baig MS, Shammas NW,Brilakis ES. Endovascular Treatment of Infrainguinal Peripheral Arterial Chronic Total Occlusions with the TruePath Device: Featured Case Series, Device Features, Handling and Procedural Outcomes. J Endovasc Ther 2014; 21(2):281-8
Roberts D, Niazi K, Miller W, Krishnan P, Gammon R, Schreiber T, Shammas NW and Clair D. Effective Endovascular Treatment of Calcified Femoropopliteal Disease with Plaque Excision Atherectomy and Distal Embolic Protection Catheterization and Cardiovascular Interventions 2014; 2014 Jan 9. doi: 10.1002/ccd.25384. [Epub ahead of print]
Shammas NW, Shammas GA , Jerin M. Differences in Patients’ Selection and Outcomes of SilverHawk Atherectomy versus Laser Atherectomy in Treating In-Stent Restenosis of the Femoropopliteal Arteries: A Retrospective Analysis from a Single Center. J Endovasc Ther 2013; 20(6):844-52. doi: 10.1583/13-4411R.1.
Shammas NW. Jetstream atherectomy for treating iatrogenic occlusion of stented common femoral artery following deployment of Angioseal closure device. J Invasive Cardiol, 2013; 25(9):475-7
Shammas NW, Shammas GA, Nader E, Jerin M, Mrad L, Ehrecke N, Shammas WJ, Voelliger CM, Hafez A, Kelly R, Reynolds E. Outcomes of Patients Treated with the Everolimus- Versus the Paclitaxel -Eluting Stents in a Consecutive Cohort of Patients at a Tertiary Medical Center . Int J Angiol 2013;22:165-170
Shammas NW, Shammas GA, Sharis P, Jerin M. Age differences in long term outcomes of coronary patients treated with drug eluting stents at a tertiary medical center. Journal of Aging Research, Article ID 471026, 4 pages. http://dx.doi.org/10.1155/2013/471026
Continued-Publications
Shammas NW. JETSTREAM atherectomy: a review of technique, tips and tricks in treating the femoropopliteal lesions. Int J Angiol 2014 (In Print)
Shammas NW. Role of Distal Protection in Percutaneous Renal Intervention for Atherosclerotic Renovascular Disease. Vascular Disease Management, 2013:10(12):E254-E258
De Borst GJ, Shammas NW. The search for reliable markers for increased carotid artery stenting–induced cerebral embolism J Endovasc Ther 2013; 20(5):695-698
Shammas NW. Editorial: Optimizing strategy in peripheral vascular interventions: the role of JETSTREAM atherectomy. J Invasive Cardiol 2013; 25 (Supplement B):2B
Shammas NW. Addressing challenges in the treatment of infrainguinal arterial disease: an endovascular specialist’s perspective. J Invasive Cardiol 2013; 25 (Supplement B):3B-6B
Shammas NW. Local delivery of thrombolysis using the Clearway irrigating balloon catheter in acute limb ischemia. J Endovasc Ther. 2013; 20: 427-30
Shammas NW, Padaria R, Coyne E. Pericarditis, myocarditis, and other cardiomyopathies. Prim Care 2013 Mar;40(1):213-36.
Shammas NW. An Overview of Optimal Endovascular Strategy in Treating the FemoropoplitealArtery: Mechanical, Biological and Procedural Factors. Int J Angiol 2013:22:1-8
Abstracts
Laham C, Jerin M, Shammas NW . 3-Dimensional Quantitative Coronary Angiography using Coronary Catheters as Objective Markers Reliably Unmasks Severe Occult Stenosis in Diffusely Diseased Vessels: New Results from the IQ-CATEGORIZE Lesions Study. Presented as a Late Breaking Clinical Trial by Laham at SCAI 2014 meeting, Las Vegas, May 28-21.
Laham C, Jerin M, Shammas NW. 2-view quantitative coronary angiographic measurements corrected for reference vessel disease can predict lesion percent plaque area stenosis as reliably as IVUS. Presented at SCAI 2014 meeting, Las Vegas, May 28-21.Catheterization and Cardiovascular Interventions 2014;83 (Supplement):S96-97 (abstract B-054)
Shammas NW, Shammas,GA, Jerin M. Differences in patients’ selection and outcomes of Silverhawk atherectomy versus laser atherectomy in treating in-stent restenosis of the femoropopliteal arteries: a retrospective analysis from a single center. Presented at TCT 2013, San Francisco, October 27-Nov 1. J. Am Coll Cardiol. 2013; Vol. 62, Issue 18, Supplement 1, Page B163
Shammas NW, Gray W, Garcia L, Dave R, Meltser H, Kasper G. Preliminary results from the Jetstream navitus system Endovascular Therapy post-market (JET) registry. Presented at TCT 2013, San Francisco, October 27-Nov 1. J. Am Coll Cardiol. 2013; Vol. 62, Issue 18, Supplement 1, Page B163
Sarode K, Mohammad A, Hadidi OF, Thomas R, Das TM, Maduka J, Abu-Fadel M, Baig MS, Gigliotti O, Dieter R, TsaiTT, Ali MI, Klein A, KumbhaniDJ, Luna M, Shammas NW, Prasad A, Hastings JL, Addo T, Brilakis E, Banerjee S. Multicenter Registry for Peripheral Arterial Disease Interventions and Outcomes (XLPAD Registry). Presented at TCT 2013, San Francisco, October 27-Nov 1. J. Am. Coll. Cardiol. Vol. 62, Issue 18, Supplement 1, Pages B158-B159
Shammas NW, Gray W, Garcia L, Dave R, Meltser H, Kasper G. Preliminary results from the Jetstream navitus system Endovascular Therapy post-market (JET) registry. Presented at C3 2013, Orlando, Florida, June 19, 2013. J Invasive Cardiology,
Shammas NW, Shammas GA. Preliminary results from the jetstream ISR registry in treating in-stent restenosis of femoropopliteal arteries. Abstract #4. Page 8, Proceedings of the 14th Annual New Cardiovascular Horizons Abstract book New Orleans, LA, June 5-7, 2013
Shammas NW, Shammas,GA, Jerin M. Differences in patients’ selection and outcomes of Silverhawk atherectomy versus laser atherectomy in treating in-stent restenosis of the femoropopliteal arteries: a retrospective analysis from a single center. Abstract #5. Page 9, Proceedings of the 14th Annual New Cardiovascular Horizons Abstract book New Orleans, LA, June 5-7, 2013
Shammas NW, Shammas GA, Nader E, Jerin M, Mrad L, Ehrecke N, Shammas WJ, Hafez A, Kelly R, Reynolds E. Outcomes of Patients Treated With The Paclitaxel- Versus The Everolimus -eluting Stents in a Consecutive Cohort of Patients at a Tertiary Medical Center. Presented at CRT 2013, Washington DC. J Am Coll Cardiol Intv. 2013;6(2_S):S16-S16
Shammas NW, Shammas GA, Jerin M. Age Differences in Long-Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center. Presented at CRT 2013, Washington DC. J Am Coll Cardiol Intv. 2013;6(2_S):S20-S21.
Shammas NW, Shammas GA, Jerin M. Gender Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center. Presented at CRT 2013, Washington DC. J Am Coll Cardiol Intv. 2013;6(2_S):S20-S20
Shammas NW, Shammas GA, Hafez A, Kelley R, Reynolds E, Shammas AN. Safety and One-Year Revascularization Outcome of Excimer Laser Ablation Therapy in Treating In-Stent Restenosis of Femoropopliteal Arteries: A Retrospective Review from a Single Center. Presented at CRT 2013, Washington DC. J Am Coll Cardiol Intv. 2013;6(2_S):S29-S30
Shammas NW. Lam R, Mustapha J, Ellichman J, Aggarwala E, Rivera et al. Orbital Atherectomy and Balloon Angioplasty vs. Balloon Angioplasty Alone in Critical Limb Ischemia: Results of the CALCIUM 360 Trial. Abstracts and Late Breaking Trials at International Symposium on Endovascular Therapy 2013, Miami, Fl. Journal of Vascular and Interventional Radiology 2013: 145.e3 DOI: 10.1016/j.jvir.2010.04.029
Book chaptersShammas NW. Management of Chronic Venous Insufficiency. In:
Bhatt Cardiovascular Interventions. A Companion to Braunwald’s
Heart Disease, Elsevier Science, 2014 (In print)
Toth PP, Shammas NW, Foreman B. Cardiovascular Medicine,
in: Rakel Textbook of Family Medicine, Elsevier Science Health
Science div, 2014 (in Print)
Shammas NW. Treatment of subacute and chronic thrombotic
occlusions of the lower extremity peripheral arteries: the role of
excimer laser. in Lasers in Cardiovascular Interventions (On
Topaz, ed.) (in Print)
Shammas NW, Padaria R, Coyne E. Pericarditis, Myocarditis and
other Cardiomyopathies. In Primary Care. Cardiovascular
Diseases Edited by Robert D. Sheeler) 2013 Mar;40(1):213-36
Thank You for The Research Program at Genesis
top related